

NETWORK Notification

Notice Date: December 1, 2024 To: CareSource Providers

From: CareSource

Subject: Avalon Q3 2024 Quarterly Policy Updates

Summary

CareSource has partnered with Avalon Healthcare Solutions for laboratory benefits management (LBM), including routine testing management (RTM), a post-service pre-payment clinical claim editing program for routine lab testing.

The RTM program is based on ensuring compliance with the lab policies located on Avalon's website.

This notification is intended to provide you notification of changes to the policies listed below. The policies appear on Avalon website upon their effective dates.

Policies

Policy Name	Plans	Effective Date
F2019: Flow Cytometry – Effective Date: 02-01-2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
G2002: Cervical Cancer Screening – Effective Date: 02-01-2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
G2007: Prostate Biopsy Specimen Analysis – Effective Date: 02-01- 2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
G2035: Prenatal Screening (Nongenetic) – Effective Date: 02-01- 2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
G2036: Hepatitis Testing – Effective Date: 02-01-2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
G2043: Celiac Disease Testing – Effective Date: 02-01-2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
G2045: Thyroid Disease Testing – Effective Date: 02-01-2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
G2048: Biochemical Markers of Alzheimer Disease and Dementia – Effective Date: 02-01-2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
G2050: Cardiovascular Disease Risk Assessment – Effective Date: 02-01- 2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025

G2051: Bone Turnover Markers Testing – Effective Date: 02-01-2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
G2059: Epithelial Cell Cytology in	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Breast Cancer Risk Assessment –		
Effective Date: 02-01-2025		
G2060: Fecal Analysis in the	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Diagnosis of Intestinal Dysbiosis and		
Fecal Microbiota Transplant Testing		
- Effective Date: 02-01-2025	OUIO DUAL CDECIAL MEEDS (D.CMD)	EEDDIIADV 4 2025
G2061: Fecal Calprotectin Testing in Adults – Effective Date: 02-01-2025	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
G2063: Testing for Diagnosis of	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Active or Latent Tuberculosis –	OTTIO BOAL OF LOIAL NEEDS (B-ONT)	TEBROART 1, 2023
Effective Date: 02-01-2025		
G2100: In Vitro Chemoresistance	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
and Chemosensitivity Assays –	orno borte or contented (b orth)	1 251(0)(1(1-1, 2020
Effective Date: 02-01-2025		
G2105: Immunopharmacologic	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Monitoring of Therapeutic Serum		·
Antibodies – Effective Date: 02-01-		
2025		
G2107: Measurement of	OHIO DUAL SPECIAL NEEDS (D-SNP)	DECEMBER 31,
Thromboxane Metabolites for ASA		2024
Resistance – Effective Date: 03-01-		
2024 to 12-31-2024		
G2110: Serum Testing for Hepatic	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Fibrosis in the Evaluation and		
Monitoring of Chronic Liver Disease – Effective Date: 02-01-2025		
G2113: Oral Cancer Screening and	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025	Offic Boal of Loial Nelbo (B-ON)	LDROART 1, 2025
G2115: Metabolite Markers of	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Thiopurines Testing – Effective Date:	,	,
02-01-2025		
G2119: Diagnostic Testing of	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Influenza – Effective Date: 02-01-		
2025		
G2121: Laboratory Testing for the	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Diagnosis of Inflammatory Bowel		
Disease – Effective Date: 02-01-		
2025	OHIO DHAL ODEOIAL MEEDO (D.OMB)	FEDDIADV 4 0005
G2123: Serum Biomarker Testing for	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Multiple Sclerosis and Related		
Neurologic Diseases – Effective Date: 02-01-2025		
G2124: Serum Tumor Markers for	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Malignancies – Effective Date: 02-	OTTO DOAL OF LOIAL NELDO (D-SINF)	LDIXOAIXI , 2020
01-2025		
G2149: Pathogen Panel Testing –	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Effective Date: 02-01-2025		
G2150: Biomarkers for Myocardial	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Infarction and Chronic Heart Failure		,
- Effective Date: 02-01-2025		

G2151: Serum Testing for Evidence of Mild Traumatic Brain Injury –	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Effective Date: 02-01-2025		
G2153: Pancreatic Enzyme Testing	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
for Acute Pancreatitis – Effective		
Date: 02-01-2025		
G2154: Folate Testing – Effective	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Date: 02-01-2025		
G2155: General Inflammation	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025		
G2156: Urine Culture Testing for	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Bacteria – Effective Date: 02-01-		·
2025		
G2157: Diagnostic Testing of	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Common Sexually Transmitted	(2 3)	
Infections – Effective Date: 02-01-		
2025		
G2158: Testing for Vector-Borne	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Infections – Effective Date: 02-01-	OTIO DOAL SELCIAL NEEDS (D-SNE)	1 LBROART 1, 2023
2025		
G2159: B-Hemolytic Streptococcus		
Testing – Effective Date: 02-01-2025		=====
G2159: B-Hemolytic Streptococcus	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025		
G2173: Gamma-glutamyl	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Transferase – Effective Date: 02-01-		
2025		
M2041: Venous and Arterial	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Thrombosis Risk Testing – Effective		
Date: 02-01-2025		
M2068: Testing for Alpha-1	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Antitrypsin Deficiency – Effective		·
Date: 02-01-2025		
M2097: Identification of	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
Microorganisms Using Nucleic Acid	(2 3)	
Probes – Effective Date: 02-01-2025		
M2112: Nerve Fiber Density Testing	OHIO DUAL SPECIAL NEEDS (D-SNP)	FEBRUARY 1, 2025
- Effective Date: 02-01-2025	OTHO BOTTE OF EOTHER TREEDS (B OTH)	1 20107 ((1 1, 2020
2.1001170 Bato. 02 01 2020		
F2019: Flow Cytometry – Effective	OHIO MARKETPLACE	FEBRUARY 1, 2025
Date: 02-01-2025	OTHO WAINING IF LAGE	LDINOMINI , 2020
		EEDDIIADV 4 2025
G2002: Cervical Cancer Screening –	OHIO MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025	OUIO MADICETTI ACE	EEDDIADV 4 0005
G2007: Prostate Biopsy Specimen	OHIO MARKETPLACE	FEBRUARY 1, 2025
Analysis – Effective Date: 02-01-		
2025		
G2035: Prenatal Screening	OHIO MARKETPLACE	FEBRUARY 1, 2025
(Nongenetic) – Effective Date: 02-01-		
2025		
G2036: Hepatitis Testing – Effective	OHIO MARKETPLACE	FEBRUARY 1, 2025
Date: 02-01-2025		
G2043: Celiac Disease Testing –	OHIO MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025		
-		

G2045: Thyroid Disease Testing – Effective Date: 02-01-2025	OHIO MARKETPLACE	FEBRUARY 1, 2025
G2048: Biochemical Markers of	OHIO MARKETPLACE	FEBRUARY 1, 2025
Alzheimer Disease and Dementia –		·
Effective Date: 02-01-2025		
G2050: Cardiovascular Disease Risk	OHIO MARKETPLACE	FEBRUARY 1, 2025
Assessment – Effective Date: 02-01-		·
2025		
G2051: Bone Turnover Markers	OHIO MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025		
G2059: Epithelial Cell Cytology in	OHIO MARKETPLACE	FEBRUARY 1, 2025
Breast Cancer Risk Assessment –		
Effective Date: 02-01-2025		
G2060: Fecal Analysis in the	OHIO MARKETPLACE	FEBRUARY 1, 2025
Diagnosis of Intestinal Dysbiosis and		
Fecal Microbiota Transplant Testing		
- Effective Date: 02-01-2025		
G2061: Fecal Calprotectin Testing in	OHIO MARKETPLACE	FEBRUARY 1, 2025
Adults – Effective Date: 02-01-2025		
G2063: Testing for Diagnosis of	OHIO MARKETPLACE	FEBRUARY 1, 2025
Active or Latent Tuberculosis –		
Effective Date: 02-01-2025		
G2100: In Vitro Chemoresistance	OHIO MARKETPLACE	FEBRUARY 1, 2025
and Chemosensitivity Assays –		
Effective Date: 02-01-2025		
G2105: Immunopharmacologic	OHIO MARKETPLACE	FEBRUARY 1, 2025
Monitoring of Therapeutic Serum		
Antibodies – Effective Date: 02-01-		
2025		
G2107: Measurement of	OHIO MARKETPLACE	DECEMBER 31,
Thromboxane Metabolites for ASA		2024
Resistance – Effective Date: 03-01-		
2024 to 12-31-2024		
G2110: Serum Testing for Hepatic	OHIO MARKETPLACE	FEBRUARY 1, 2025
Fibrosis in the Evaluation and		
Monitoring of Chronic Liver Disease		
- Effective Date: 02-01-2025		
G2113: Oral Cancer Screening and	OHIO MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025	0.110.111.77.77.77	
G2115: Metabolite Markers of	OHIO MARKETPLACE	FEBRUARY 1, 2025
Thiopurines Testing – Effective Date:		
02-01-2025	OLUO MARKETRI AGE	FEDDUADY (2007
G2119: Diagnostic Testing of	OHIO MARKETPLACE	FEBRUARY 1, 2025
Influenza – Effective Date: 02-01-		
2025	OLUO MADVETE: 105	FEDDUADY (2007
G2121: Laboratory Testing for the	OHIO MARKETPLACE	FEBRUARY 1, 2025
Diagnosis of Inflammatory Bowel		
Disease – Effective Date: 02-01-		
2025	OLUO MARKETRI AGE	FEDDUADY (2005
G2123: Serum Biomarker Testing for	OHIO MARKETPLACE	FEBRUARY 1, 2025
Multiple Sclerosis and Related		
Neurologic Diseases – Effective		
Date: 02-01-2025		

G2124: Serum Tumor Markers for	OHIO MARKETPLACE	FEBRUARY 1, 2025
Malignancies – Effective Date: 02-		
01-2025		
G2149: Pathogen Panel Testing –	OHIO MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025		1 25.10,
G2150: Biomarkers for Myocardial	OHIO MARKETPLACE	FEBRUARY 1, 2025
	ONIO WARRETPLACE	FEBRUART 1, 2025
Infarction and Chronic Heart Failure		
- Effective Date: 02-01-2025		
G2151: Serum Testing for Evidence	OHIO MARKETPLACE	FEBRUARY 1, 2025
of Mild Traumatic Brain Injury –		
Effective Date: 02-01-2025		
G2153: Pancreatic Enzyme Testing	OHIO MARKETPLACE	FEBRUARY 1, 2025
for Acute Pancreatitis – Effective		
Date: 02-01-2025		
G2154: Folate Testing – Effective	OHIO MARKETPLACE	FEBRUARY 1, 2025
Date: 02-01-2025	OTHO WARRETT EAGE	TEBROART 1, 2023
G2155: General Inflammation		EEDDIIADV 4 2025
	OHIO MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025	01110 144 51/5751 1 05	FEBRUARY (2227
G2156: Urine Culture Testing for	OHIO MARKETPLACE	FEBRUARY 1, 2025
Bacteria – Effective Date: 02-01-		
2025		
G2157: Diagnostic Testing of	OHIO MARKETPLACE	FEBRUARY 1, 2025
Common Sexually Transmitted		
Infections – Effective Date: 02-01-		
2025		
G2158: Testing for Vector-Borne	OHIO MARKETPLACE	FEBRUARY 1, 2025
Infections – Effective Date: 02-01-	OTHO WATER EACE	1 251(6) ((1 1, 2020
2025		
G2159: B-Hemolytic Streptococcus		
Testing – Effective Date: 02-01-2025	01110 144 51/5 751 4 05	
G2159: B-Hemolytic Streptococcus	OHIO MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025		
G2173: Gamma-glutamyl	OHIO MARKETPLACE	FEBRUARY 1, 2025
Transferase – Effective Date: 02-01-		
2025		
M2041: Venous and Arterial	OHIO MARKETPLACE	FEBRUARY 1, 2025
Thrombosis Risk Testing – Effective	_	, , ,
Date: 02-01-2025		
M2068: Testing for Alpha-1	OHIO MARKETPLACE	FEBRUARY 1, 2025
Antitrypsin Deficiency – Effective	OTHO WARRETT LAGE	
Date: 02-01-2025		
M2097: Identification of		EEDDUADV 4 0005
	OHIO MARKETPLACE	FEBRUARY 1, 2025
Microorganisms Using Nucleic Acid		
Probes – Effective Date: 02-01-2025		
M2112: Nerve Fiber Density Testing	OHIO MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025		
F2019: Flow Cytometry – Effective	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Date: 02-01-2025		
G2002: Cervical Cancer Screening -	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025		
555 5 4.5. 52 61 2020	1	1

G2007: Prostate Biopsy Specimen	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Analysis – Effective Date: 02-01-		
2025		
G2035: Prenatal Screening	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
(Nongenetic) – Effective Date: 02-01-		
2025		
G2036: Hepatitis Testing – Effective	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Date: 02-01-2025		·
G2043: Celiac Disease Testing –	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025		,
G2045: Thyroid Disease Testing –	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025		, , , , ,
G2048: Biochemical Markers of	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Alzheimer Disease and Dementia –		, , , , , , , , , , , , , , , , , , , ,
Effective Date: 02-01-2025		
G2050: Cardiovascular Disease Risk	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Assessment – Effective Date: 02-01-		
2025		
G2051: Bone Turnover Markers	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025		. 25.137.111 1, 2020
G2059: Epithelial Cell Cytology in	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Breast Cancer Risk Assessment –	SESTICITY WITH CITE ET SE	1 251(6) ((1 1, 2626
Effective Date: 02-01-2025		
G2060: Fecal Analysis in the	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Diagnosis of Intestinal Dysbiosis and	OLONGIA WANTEN LAGE	1 LBROART 1, 2025
Fecal Microbiota Transplant Testing		
- Effective Date: 02-01-2025		
G2061: Fecal Calprotectin Testing in	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Adults – Effective Date: 02-01-2025	GEORGIA WARRETPLACE	FEBRUART 1, 2025
G2063: Testing for Diagnosis of	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Active or Latent Tuberculosis –	GEORGIA WARRETPLACE	FEBRUART 1, 2023
Effective Date: 02-01-2025		
G2100: In Vitro Chemoresistance	GEORGIA MARKETPLACE	FERRIARY 4, 2025
	GEORGIA WARRETPLACE	FEBRUARY 1, 2025
and Chemosensitivity Assays –		
Effective Date: 02-01-2025		FEDDIADY 4, 0005
G2105: Immunopharmacologic	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Monitoring of Therapeutic Serum		
Antibodies – Effective Date: 02-01-		
2025	CEODOLA MADICETRI ACE	DECEMBED 04
G2107: Measurement of	GEORGIA MARKETPLACE	DECEMBER 31,
Thromboxane Metabolites for ASA		2024
Resistance – Effective Date: 03-01-		
2024 to 12-31-2024	OFODOLA MADICETRI AGE	FEDDUADY 4 0005
G2110: Serum Testing for Hepatic	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Fibrosis in the Evaluation and		
Monitoring of Chronic Liver Disease		
- Effective Date: 02-01-2025	050000000000000000000000000000000000000	FEDDINA
G2113: Oral Cancer Screening and	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025	050000000000000000000000000000000000000	FERRING
G2115: Metabolite Markers of	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Thiopurines Testing – Effective Date:		
02-01-2025		

G2119: Diagnostic Testing of Influenza – Effective Date: 02-01-	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
G2121: Laboratory Testing for the	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Diagnosis of Inflammatory Bowel		
Disease – Effective Date: 02-01-		
2025	GEORGIA MARKETPLACE	FEDDUADY 4, 2025
G2123: Serum Biomarker Testing for Multiple Sclerosis and Related	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Neurologic Diseases – Effective		
Date: 02-01-2025		
G2124: Serum Tumor Markers for	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Malignancies – Effective Date: 02-		
01-2025		
G2149: Pathogen Panel Testing –	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025 G2150: Biomarkers for Myocardial	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Infarction and Chronic Heart Failure	GEORGIA IVIARRETPLACE	FEDRUART 1, 2020
- Effective Date: 02-01-2025		
G2151: Serum Testing for Evidence	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
of Mild Traumatic Brain Injury –		,
Effective Date: 02-01-2025		
G2153: Pancreatic Enzyme Testing	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
for Acute Pancreatitis – Effective		
Date: 02-01-2025	CEODOIA MADICETRI ACE	FEDDLIADY 4, 2025
G2154: Folate Testing – Effective Date: 02-01-2025	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
G2155: General Inflammation	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025		,, , ,,
G2156: Urine Culture Testing for	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Bacteria – Effective Date: 02-01-		
2025		
G2157: Diagnostic Testing of	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Common Sexually Transmitted Infections – Effective Date: 02-01-		
2025		
G2158: Testing for Vector-Borne	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Infections – Effective Date: 02-01-		- · · · · · · · · · · · · · · · · · · ·
2025		
G2159: B-Hemolytic Streptococcus		
Testing – Effective Date: 02-01-2025	050000000000000000000000000000000000000	FEDDINES (1 222
G2159: B-Hemolytic Streptococcus	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025	GEORGIA MARKETPLACE	EERDIIADV 1 2025
G2173: Gamma-glutamyl Transferase – Effective Date: 02-01-	GEORGIA IVIARNE I PLACE	FEBRUARY 1, 2025
2025		
M2041: Venous and Arterial	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Thrombosis Risk Testing – Effective	- · · - · · -	- ', ===
Date: 02-01-2025		
M2068: Testing for Alpha-1	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Antitrypsin Deficiency – Effective		
Date: 02-01-2025		

M2097: Identification of	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
Microorganisms Using Nucleic Acid		. ==:::::::::::::::::::::::::::::::::::
Probes – Effective Date: 02-01-2025		
M2112: Nerve Fiber Density Testing	GEORGIA MARKETPLACE	FEBRUARY 1, 2025
- Effective Date: 02-01-2025		
F2019: Flow Cytometry – Effective Date: 02-01-2025	GEORGIA DUAL SPECIAL NEEDS (D- SNP)	FEBRUARY 1, 2025
G2002: Cervical Cancer Screening –	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Effective Date: 02-01-2025	SNP)	
G2007: Prostate Biopsy Specimen	GEORGIA DUAL SPÉCIAL NEEDS (D-	FEBRUARY 1, 2025
Analysis – Effective Date: 02-01-	SNP)	·
2025	,	
G2035: Prenatal Screening	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
(Nongenetic) – Effective Date: 02-01-	SNP)	
2025		
G2036: Hepatitis Testing – Effective	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Date: 02-01-2025	SNP)	
G2043: Celiac Disease Testing –	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Effective Date: 02-01-2025	SNP)	
G2045: Thyroid Disease Testing – Effective Date: 02-01-2025	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
G2048: Biochemical Markers of	SNP) GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Alzheimer Disease and Dementia –	SNP)	FEDRUART 1, 2023
Effective Date: 02-01-2025	ONI)	
G2050: Cardiovascular Disease Risk	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Assessment – Effective Date: 02-01-	SNP)	1 251(0) ((1 1, 2020
2025	,	
G2051: Bone Turnover Markers	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025	SNP)	
G2059: Epithelial Cell Cytology in	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Breast Cancer Risk Assessment –	SNP)	
Effective Date: 02-01-2025		
G2060: Fecal Analysis in the	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Diagnosis of Intestinal Dysbiosis and	SNP)	
Fecal Microbiota Transplant Testing – Effective Date: 02-01-2025		
G2061: Fecal Calprotectin Testing in	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Adults – Effective Date: 02-01-2025	SNP)	1 LDINOMINI 1, 2023
G2063: Testing for Diagnosis of	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Active or Latent Tuberculosis –	SNP)	
Effective Date: 02-01-2025	,	
G2100: In Vitro Chemoresistance	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
and Chemosensitivity Assays –	SNP)	
Effective Date: 02-01-2025		
G2105: Immunopharmacologic	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Monitoring of Therapeutic Serum	SNP)	
Antibodies – Effective Date: 02-01-		
2025	OFODOIA DIIAL ODFOIAL NEEDO (D	
G2107: Measurement of Thromboxane Metabolites for ASA	GEORGIA DUAL SPECIAL NEEDS (D-	DECEMBER 31, 2024
Resistance – Effective Date: 03-01-	SNP)	ZUZ4
2024 to 12-31-2024		
		I

		T =====
G2110: Serum Testing for Hepatic	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Fibrosis in the Evaluation and	SNP)	
Monitoring of Chronic Liver Disease		
Effective Date: 02-01-2025		
G2113: Oral Cancer Screening and	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025	SNP)	
G2115: Metabolite Markers of	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Thiopurines Testing – Effective Date:	SNP)	
02-01-2025	,	
G2119: Diagnostic Testing of	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Influenza – Effective Date: 02-01-	SNP)	,
2025	,	
G2121: Laboratory Testing for the	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Diagnosis of Inflammatory Bowel	SNP)	
Disease – Effective Date: 02-01-	5111)	
2025		
G2123: Serum Biomarker Testing for	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Multiple Sclerosis and Related	SNP)	I LBROART 1, 2025
Neurologic Diseases – Effective	SINF)	
Date: 02-01-2025		
G2124: Serum Tumor Markers for	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
		FEBRUART 1, 2025
Malignancies – Effective Date: 02-	SNP)	
01-2025	OFODOLA DILAL ODFOLAL NIFEDO /D	EEDDIIADV 4 0005
G2149: Pathogen Panel Testing –	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Effective Date: 02-01-2025	SNP)	55551145\/ 4 0005
G2150: Biomarkers for Myocardial	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Infarction and Chronic Heart Failure	SNP)	
- Effective Date: 02-01-2025		=======================================
G2151: Serum Testing for Evidence	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
of Mild Traumatic Brain Injury –	SNP)	
Effective Date: 02-01-2025		
G2153: Pancreatic Enzyme Testing	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
for Acute Pancreatitis – Effective	SNP)	
Date: 02-01-2025		
G2154: Folate Testing – Effective	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Date: 02-01-2025	SNP)	
G2155: General Inflammation	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025	SNP)	
G2156: Urine Culture Testing for	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Bacteria – Effective Date: 02-01-	SNP)	
2025		
G2157: Diagnostic Testing of	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Common Sexually Transmitted	SNP)	·
Infections – Effective Date: 02-01-	,	
2025		
G2158: Testing for Vector-Borne	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Infections – Effective Date: 02-01-	SNP)	, ,, _ , _ ,
2025	<i>,</i>	
G2159: B-Hemolytic Streptococcus		
Testing – Effective Date: 02-01-2025		
G2159: B-Hemolytic Streptococcus	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025	SNP)	
	-··· <i>)</i>	l .

C2172: Commo glutomyl	GEORGIA DUAL SPECIAL NEEDS (D-	EEDDIIADV 1 2025
G2173: Gamma-glutamyl Transferase – Effective Date: 02-01-	SNP)	FEBRUARY 1, 2025
2025	SINF)	
M2041: Venous and Arterial	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Thrombosis Risk Testing – Effective	SNP)	1 LBROART 1, 2023
Date: 02-01-2025	Jan 7	
M2068: Testing for Alpha-1	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Antitrypsin Deficiency – Effective	SNP)	
Date: 02-01-2025	,	
M2097: Identification of	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
Microorganisms Using Nucleic Acid	SNP)	·
Probes – Effective Date: 02-01-2025	·	
M2112: Nerve Fiber Density Testing	GEORGIA DUAL SPECIAL NEEDS (D-	FEBRUARY 1, 2025
- Effective Date: 02-01-2025	SNP)	
F2019: Flow Cytometry – Effective	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Date: 02-01-2025		
G2002: Cervical Cancer Screening –	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025		
G2007: Prostate Biopsy Specimen	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Analysis – Effective Date: 02-01-		
2025	LIENTHOLO (MARKETEL AGE	5555145V 4 0005
G2035: Prenatal Screening	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
(Nongenetic) – Effective Date: 02-01-		
2025 G2036: Hepatitis Testing – Effective	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Date: 02-01-2025	RENTOCKT WARRETF LAGE	I LDINOAINI 1, 2023
G2043: Celiac Disease Testing –	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025	TENTOON WINNELD ENGE	I EBITOMITI I, 2020
G2045: Thyroid Disease Testing –	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025		. ==:::::::::::::::::::::::::::::::::::
G2048: Biochemical Markers of	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Alzheimer Disease and Dementia –		,
Effective Date: 02-01-2025		
G2050: Cardiovascular Disease Risk	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Assessment – Effective Date: 02-01-		
2025		
G2051: Bone Turnover Markers	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025		
G2059: Epithelial Cell Cytology in	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Breast Cancer Risk Assessment –		
Effective Date: 02-01-2025	IZENITUOIOZANA DIZETTUA OE	EEDDUADVA 0005
G2060: Fecal Analysis in the	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Diagnosis of Intestinal Dysbiosis and		
Fecal Microbiota Transplant Testing – Effective Date: 02-01-2025		
G2061: Fecal Calprotectin Testing in	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Adults – Effective Date: 02-01-2025	NENTOONT WANNETFLAGE	LDNUMN 1, 2020
G2063: Testing for Diagnosis of	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Active or Latent Tuberculosis –	RENTOOKI WAKKEII LAOL	LDIXOAKI 1, 2020
Effective Date: 02-01-2025		

G2100: In Vitro Chemoresistance	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
and Chemosensitivity Assays –		
Effective Date: 02-01-2025		
G2105: Immunopharmacologic	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Monitoring of Therapeutic Serum		
Antibodies – Effective Date: 02-01-		
2025		
G2107: Measurement of	KENTUCKY MARKETPLACE	DECEMBER 31,
Thromboxane Metabolites for ASA	REIVIOORI WARRETT EXCE	2024
Resistance – Effective Date: 03-01-		2024
2024 to 12-31-2024		
	KENTLICKY MADKETDI ACE	FERRILARY 1 2025
G2110: Serum Testing for Hepatic	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Fibrosis in the Evaluation and		
Monitoring of Chronic Liver Disease		
- Effective Date: 02-01-2025		
G2113: Oral Cancer Screening and	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025		
G2115: Metabolite Markers of	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Thiopurines Testing – Effective Date:		
02-01-2025		
G2119: Diagnostic Testing of	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Influenza – Effective Date: 02-01-		, , , , , , , , , , , , , , , , , , , ,
2025		
G2121: Laboratory Testing for the	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Diagnosis of Inflammatory Bowel	RENTOCKT WARRETF LAGE	I LBROART 1, 2025
Disease – Effective Date: 02-01-		
2025	LIENTHOLOGA MADICETTI AGE	FEDDUADY 4 0005
G2123: Serum Biomarker Testing for	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Multiple Sclerosis and Related		
Neurologic Diseases – Effective		
Date: 02-01-2025		
G2124: Serum Tumor Markers for	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Malignancies – Effective Date: 02-		
01-2025		
G2149: Pathogen Panel Testing –	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Effective Date: 02-01-2025		,
G2150: Biomarkers for Myocardial	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Infarction and Chronic Heart Failure	REIVIOORI WARRETT EXOL	1 251(6) (1(1-1, 2020
- Effective Date: 02-01-2025		
G2151: Serum Testing for Evidence	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
	RENTUCKT WARRETPLACE	FEBRUART 1, 2025
of Mild Traumatic Brain Injury –		
Effective Date: 02-01-2025	1/ENELIQIO/ MADI/ETDI AGE	
G2153: Pancreatic Enzyme Testing	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
for Acute Pancreatitis – Effective		
Date: 02-01-2025		
G2154: Folate Testing – Effective	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Date: 02-01-2025		
G2155: General Inflammation	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025		
G2156: Urine Culture Testing for	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
Bacteria – Effective Date: 02-01-		131 1, 2326
2025		
G2157: Diagnostic Testing of	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
	KLITTOOKT WAKKLIT LAGE	1 LDROART 1, 2020
Common Sexually Transmitted		

Infections – Effective Date: 02-01- 2025		
G2158: Testing for Vector-Borne Infections – Effective Date: 02-01- 2025	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
G2159: B-Hemolytic Streptococcus Testing – Effective Date: 02-01-2025		
G2159: B-Hemolytic Streptococcus Testing – Effective Date: 02-01-2025	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
G2173: Gamma-glutamyl Transferase – Effective Date: 02-01- 2025	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
M2041: Venous and Arterial Thrombosis Risk Testing – Effective Date: 02-01-2025	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
M2068: Testing for Alpha-1 Antitrypsin Deficiency – Effective Date: 02-01-2025	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
M2097: Identification of Microorganisms Using Nucleic Acid Probes – Effective Date: 02-01-2025	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
M2112: Nerve Fiber Density Testing – Effective Date: 02-01-2025	KENTUCKY MARKETPLACE	FEBRUARY 1, 2025
50040 FI O 1 1 FE 1	WEST MESON AND METOLOGIC	EEDDIM DV 4 0005
F2019: Flow Cytometry – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2002: Cervical Cancer Screening – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2007: Prostate Biopsy Specimen Analysis – Effective Date: 02-01- 2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2035: Prenatal Screening (Nongenetic) – Effective Date: 02-01- 2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2036: Hepatitis Testing – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2043: Celiac Disease Testing – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2045: Thyroid Disease Testing – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2048: Biochemical Markers of Alzheimer Disease and Dementia – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2050: Cardiovascular Disease Risk Assessment – Effective Date: 02-01- 2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2051: Bone Turnover Markers Testing – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2059: Epithelial Cell Cytology in Breast Cancer Risk Assessment – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2060: Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025

Fecal Microbiota Transplant Testing – Effective Date: 02-01-2025		
G2061: Fecal Calprotectin Testing in Adults – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2063: Testing for Diagnosis of Active or Latent Tuberculosis – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2100: In Vitro Chemoresistance and Chemosensitivity Assays – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2105: Immunopharmacologic Monitoring of Therapeutic Serum Antibodies – Effective Date: 02-01- 2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2107: Measurement of Thromboxane Metabolites for ASA Resistance – Effective Date: 03-01- 2024 to 12-31-2024	WEST VIRGINIA MARKETPLACE	DECEMBER 31, 2024
G2110: Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2113: Oral Cancer Screening and Testing – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2115: Metabolite Markers of Thiopurines Testing – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2119: Diagnostic Testing of Influenza – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2121: Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2123: Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2124: Serum Tumor Markers for Malignancies – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2149: Pathogen Panel Testing – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2150: Biomarkers for Myocardial Infarction and Chronic Heart Failure – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2151: Serum Testing for Evidence of Mild Traumatic Brain Injury – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2153: Pancreatic Enzyme Testing for Acute Pancreatitis – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
G2154: Folate Testing – Effective Date: 02-01-2025	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025

COAFF. Comencil inflammention	MICCE VIDOINIA MADIZETDI ACE	EEDDIIADV 4 2025
G2155: General Inflammation	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025	VALCET VIDCINIA MADIZETDI ACE	EEDDLIADY 1, 2025
G2156: Urine Culture Testing for	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
Bacteria – Effective Date: 02-01-		
2025		
G2157: Diagnostic Testing of	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
Common Sexually Transmitted		
Infections – Effective Date: 02-01-		
2025		
G2158: Testing for Vector-Borne	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
Infections – Effective Date: 02-01-		
2025		
G2159: B-Hemolytic Streptococcus		
Testing – Effective Date: 02-01-2025		
G2159: B-Hemolytic Streptococcus	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
Testing – Effective Date: 02-01-2025		
G2173: Gamma-glutamyl	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
Transferase – Effective Date: 02-01-		
2025		
M2041: Venous and Arterial	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
Thrombosis Risk Testing – Effective		,
Date: 02-01-2025		
M2068: Testing for Alpha-1	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
Antitrypsin Deficiency – Effective		,
Date: 02-01-2025		
M2097: Identification of	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
Microorganisms Using Nucleic Acid		<u> </u>
Probes – Effective Date: 02-01-2025		
M2112: Nerve Fiber Density Testing	WEST VIRGINIA MARKETPLACE	FEBRUARY 1, 2025
- Effective Date: 02-01-2025		

Trial Claim Advice Tool

Providers may use the Trial Claim Advice tool to review claims with laboratory services for adherence and consistency with CareSource laboratory policies. This is a simulation tool and does not guarantee approval or reimbursement of claims. You can access the Trial Claim Advice Tool on the CareSource Provider Portal.

Multi-Multi-P-3458654